Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant

Inclusion Criteria: * ≥21 to ≤ 70 years of age at time of consent * Seeking treatment for nasal airway obstruction (NAO) symptoms due primarily to cartilaginous nasal septal deviation * Willing to undergo a nasal implant procedure * NOSE score ≥30 at Baseline Visit * Non-calcified, mobile cartilaginous nasal septal deviation Exclusion Criteria: * Target nasal septal deviation that is calcified or non-mobile * Previous septoplasty or rhinoplasty * Having a concurrent ENT procedure, other than turbinate reduction * Saddle nose deformity * Congenital nasal defect * Documented evidence that middle meatus is not visualized on endoscopic exam due to severe septal deviation * Turbinate reduction within the past six (6) months * Permanent implant or dilator in the nose * History of nasal vasculitis, unhealed wounds, cartilaginous nasal septal perforation or mucosal irregularities * Active infection at the impllantation site e.g., folliculitis * Current or chronic systemic steroid and/or has had radiation exposure or active chemotherapy in the treatment area * Polyps or pathology, other than turbinate hypertrophy, that may be primary contributor to airway obstruction, in the opinion of the Investigator * History of a significant bleeding disorder(s) and or taking current prescription blood thinner medication * Hypersensitivity to any investigational device materials inclusing known or suspected allergy to poly(dioxanone) (PDO) or other bioabsorbable materials * Major medical condit…